AbbVie (NASDAQ:ABBV) is basically a one-trick pony. The trick is an immunosuppressant called Humira, prescribed to fight rheumatoid arthritis and other conditions. It’s the best-selling drug in the world, bringing in $18.4 billion in 2017, but that might not be sufficient to support the future of AbbVie stock. While protected against direct competition in the U.S. until 2023, Humira is already facing biosimilars in Europe, as its protections there disappear.
For now, the good times roll on. AbbVie is due to report earnings Jan. 25, expecting sales of $8.36 billion for a 2018 total of $32.8 billion , 16% ahead of 2017’s $28.2 billion. Net income of $1.92 per share will bring that total to $6.92 per share for the year. But, as they say of both athletes and great beauties, Father Time is undefeated. AbbVie still faces a patent cliff, and growing opposition to rising prices. Nothing lasts forever. What works this year may not work next year. Know that before you buy AbbVie stock.
Source: InvestorPlace
Related Articles:
- 2 Low P/E Value-Stocks, Yielding 4% Or Higher
- 5 Stocks With A Low Debt To Total Capital
- Should You Sell A Dividend Stock After A Dividend Cut?
- All Investing Involves Risk
- 4 Dividend Stocks With Room To Increase Their Payout
________________________________________________________________
Subscribe to:
Post Comments (Atom)
Popular Posts Last 30 Days
-
Each of these high-yield dividend stocks has a dividend yield exceeding 6.5%. That’s is a very high dividend yield few stocks have. In addit...
-
Because their financials must support a monthly dividend payment, the companies in this space are stable by nature — their operations are st...
-
While there are a number of factors responsible for pushing the stock market lower, the spread of COVID-19 looks to be the match that lit th...
-
Dividend payments are, by nature, a conservative strategy for companies to use, and as a rule of thumb the more conservative companies are l...
-
This stock has plunged by 50%. Only two mortgage REIT analysts warned investors away from shares before it happened. The market overreacted....
-
So if the economy does putter out, what should you do with your money? You could do worse than bet on recession-proof dividend stocks. That ...
-
So what should investors do amid the panic? They could do worse than own top dividend stocks. The recent stock market crash has turned some ...
-
As veteran traders will attest, though, nothing lasts forever. It might not be a bad idea to start adding exposure to the market's lagga...
-
In a soaring market, a few percentages of dividends may not seem like much. Over the past few months, the Dow Jones Industrial Average, the ...
-
For most investors, this is not a time to panic. Rather than take a flight to safety, now is a time to take a flight to quality. And when in...
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.